New River Pharmaceuticals Inc

New River Pharmaceuticals — Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 2007

8 slides from New River Pharmaceuticals's conference presentation, Feb 6, 2007

  1. Slide 1: Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

    Slide 1: Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference

    Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference February 6, 2007 RJ Kirk (Chairman and CEO) Krish Krishnan (CFO/COO)

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views as to the Company’s clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forward-looking statement

  3. Slide 3: Investment Thesis

    Slide 3: Investment Thesis

    Investment Thesis A platform technology yielding proprietary products that offer significant clinical advantages with low technical risk and short development pathway, facing timely market demand, in a favorable regulatory climate.

  4. Slide 4: Pipeline Update

    Slide 4: Pipeline Update

    Pipeline Update Product Indication Status Vyvanse® (NRP104) Pediatric ADHD PDUFA - February 24, 2007 Launch anticipated in Q2 2007 NRP104 Adult ADHD Top line efficacy and safety data in April 2007 sNDA anticipated to be filed in 2Q 2007 NRP409 Hypo thyroidis m Top line PK clinical data in 1Q 2007 NR

  5. Slide 5: Vyvanse Commercialization

    Slide 5: Vyvanse Commercialization

    Vyvanse ® Commercialization n New River has exercised its co-promotion right under the Shire collaboration agreement n New River has hired James Shaffer as Vice President, Sales and Marketing n New River anticipates hiring ~ 100 sales representatives before product launch in 2Q n New River and Shire

  6. Slide 6: NRP 104: Design of Phase 3 Adult Studies

    Slide 6: NRP 104: Design of Phase 3 Adult Studies

    NRP 104: Design of Phase 3 Adult Studies Dr. Joseph Biederman: Principal Investigator Trial n Randomized, double-blind, placebo-controlled • NRP104: 30mg, 50mg & 70mg • adults (18-55 years) with ADHD • sites; 4-week trial n Primary objective: efficacy and safety (ADHD-RS) n Secondary objective: Dose

  7. Slide 7: Research Areas

    Slide 7: Research Areas

    Research Areas n Oxycodone / Hydromorphone n T4 conjugates n Cardiovascular

  8. Slide 8: New River Pharmaceuticals

    Slide 8: New River Pharmaceuticals

    N EW RIVER PHARMACEUTICALS

Source: SEC EDGAR · 8-K filed Feb 6, 2007

More decks from New River Pharmaceuticals Inc